论文部分内容阅读
目的:探讨端粒酶抑制剂XAV939联合奈达铂对HeLa细胞增殖和凋亡的影响以及XAV939与铂类药物联合作用。方法:采用MTT法检测端粒酶抑制剂XAV939、奈达铂分别作用及联合用药时HeLa时的细胞抑制率,Hoechst33258染色检测细胞凋亡情况,并利用中效原理判定XAV939和奈达铂联合应用的效果。结果:端粒酶抑制剂XAV939及奈达铂均对HeLa细胞有明显的杀伤作用,并呈现浓度依赖性,其中XAV939无明显时间依赖性,奈达铂有较强时间依赖性。两药在低效应剂量(fa<0.3)时,合用指数(CI)>1;在高效应剂量(fa≥0.3)时,CI<1。结论:端粒酶抑制剂XAV939单独可抑制HeLa细胞的增殖;与奈达铂大剂量合用时效应为协同作用,小剂量合用时效应为拮抗作用。
Objective: To investigate the effects of telomerase inhibitor XAV939 combined with nedaplatin on proliferation and apoptosis of HeLa cells and the synergistic effect of XAV939 and platinum drugs. Methods: The inhibitory rates of telomerase inhibitor XAV939 and nedaplatin were detected by MTT assay. The cell apoptosis rate was detected by HeLa staining. Hoechst33258 staining was used to detect the cell apoptosis. The combination of XAV939 and nedaplatin Effect. Results: The telomerase inhibitors XAV939 and nedaplatin both had a significant killing effect on HeLa cells in a dose-dependent manner. XAV939 had no significant time-dependent effect and nedaplatin had a strong time-dependent effect. The combination index (CI) was> 1 for both agents at low effective doses (fa <0.3) and CI <1 at high effective doses (fa> 0.3) CONCLUSION: Telomerase inhibitor XAV939 can inhibit the proliferation of HeLa cells alone. Synergistic effect with large dose of nedaplatin is synergistic. Combination of low dose of XAV939 with antagonist effect of antagonism.